newsfilter
← Latest News
Business Wire·

Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer

RAMP 201 study supported FDA Accelerated Approval of AVMAPKI FAKZYNJA CO-PACK for treatment of KRAS-mutated recurrent LGSOC following prior systemic therapy Across patients with KRAS wild-type and KRAS-mutated